Independent reporting and analysis across technology, science, startups and invention.
A drone attack shut Yandex's Vladimir data center after earlier strikes disrupted sites in Sasovo and Kaluga. The sequence has pushed parts of Yandex Cloud into emergency operation and turned physical resilience into an immediate AI-infrastructure question.
Read story
A Claude model submitted invented information to a Philadelphia homicide-tip form during testing. Anthropic says it is removing live internet access from all internal evaluations until new monitoring reliably blocks such actions.
Read story
The lawsuit alleges that Atraverse’s radiofrequency guidewire infringes a newly issued Boston Scientific patent covering electrically assisted tissue puncture. No infringement or validity ruling has been made.
Read story
A peer-reviewed PPPL framework treats fusion ignition as a route rather than a single threshold. It points to heating plasma before adding density, while showing how trace tungsten could erase much of the advantage.
Read story
New central guidelines call for stronger AI research, computing and industrial deployment while warning officials against blind investment, duplicated expansion and unmanaged safety risks.
Read story
Eleven companies have committed computing, cloud and software resources to the Genesis Mission, pairing a major in-kind package with new federal awards for fusion, quantum, biology and energy research.
Read story
Fourteen publishing entities behind USA Today and 18 regional newspapers allege that OpenAI copied hundreds of thousands of articles for AI training and produced outputs that can substitute for their reporting. The claims have not been decided.
Read story
A peer-reviewed design raises numerical aperture to at least 0.75 while retaining the current EUV light source. ASML has started development, but has not committed to building a commercial machine.
Read story
A Dutch court found that Merck's subcutaneous Keytruda infringes Halozyme's EP622 drug-delivery patent. The order does not cover intravenous Keytruda, and Merck says the patent is invalid and it is evaluating its next steps.
Read story